Michael K. Handley

Mike is a successful life science business professional with over 23 years of cross-functional experience in drug/device commercialization, operations, mergers/acquisitions, regulatory/clinical affairs, venture formation/financing, market development, and partnering/licensing. Mike has successfully assisted or led in the global commercialization of seventeen devices or drugs that account for over three billion dollars of sales annually. He has experience successfully leading management teams in a variety of capacities in high-growth organizations and has secured millions of dollars in venture capital.

Currently, Mike is serving as Chief Executive Officer & Director of Statera Biopharma, Inc. (formerly Cytocom, Inc.) Statera has a pipeline of drugs that target immune dysfunction, inflammation, cancer, and viruses. Statera uses immune modulation as a cornerstone for mitigating and correcting disease. This new approach is focused on a systems biology approach in which multiple biological pathways are targeted simultaneously with the immune system thus increasing the efficacy and decreasing toxicity.